Hormone Receptor-Positive Breast Cancer Clinical Trials

27 recruitingLast updated: June 18, 2026

There are 27 actively recruiting hormone receptor-positive breast cancer clinical trials across 17 countries. Studies span Phase 2, Phase 1, Phase 4, Not Applicable. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Hormone Receptor-Positive Breast Cancer Trials at a Glance

27 actively recruiting trials for hormone receptor-positive breast cancer are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Houston, Boston, and Nashville. Lead sponsors running hormone receptor-positive breast cancer studies include Memorial Sloan Kettering Cancer Center, BeOne Medicines, and Baylor Breast Care Center.

Browse hormone receptor-positive breast cancer trials by phase

Treatments under study

About Hormone Receptor-Positive Breast Cancer Clinical Trials

Looking for clinical trials for Hormone Receptor-Positive Breast Cancer? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Receptor-Positive Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Receptor-Positive Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting

EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

Hormone Receptor-Positive Breast Cancer
Tel-Aviv Sourasky Medical Center19 enrolled1 locationNCT07646171
Recruiting
Phase 2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple-Negative Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor-Positive Breast Carcinoma+1 more
Laura Huppert, MD, BA36 enrolled1 locationNCT06224673
Recruiting
Phase 1

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled15 locationsNCT06756932
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Phase 2

Study of Screening Brain MRIs in Stage IV Breast Cancer

Triple-Negative Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute170 enrolled2 locationsNCT05115474
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2

ETHAN - ET for Male BC

Hormone Receptor-Positive Breast CancerMale Breast CancerHormone Receptor-Negative Breast Carcinoma
Jose Pablo Leone60 enrolled8 locationsNCT05501704
Recruiting
Phase 1Phase 2

VS-6766+Abema+Fulv in Met HR+/HER- BC

Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks63 enrolled3 locationsNCT05608252
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 2

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Breast NeoplasmsAbemaciclibHormone Receptor-Positive Breast Cancer+4 more
Hubei Cancer Hospital60 enrolled1 locationNCT07264998
Recruiting
Phase 1Phase 2

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Metastatic Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Ellipses Pharma95 enrolled14 locationsNCT05573126
Recruiting
Phase 2

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+1 more
University of California, Irvine20 enrolled1 locationNCT05524584
Recruiting
Phase 4

A Study of Revaree Plus in People With Breast Cancer

Breast CancerStage III Breast CancerHormone Receptor-Positive Breast Cancer+8 more
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07042581
Recruiting
Phase 2

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

HER2-negative Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Hormone Receptor-Positive Breast Cancer+3 more
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Phase 2

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

HER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
Rutgers, The State University of New Jersey40 enrolled7 locationsNCT06518837
Recruiting
Phase 2

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O.75 enrolled3 locationsNCT06263543